Settlement

Lidoderm Reverse Payment

On March 20, 2018, End-Payor Plaintiffs, on behalf of themselves and the End-Payor Class, entered into separate settlement agreements with (a) Defendant Endo Pharmaceuticals Inc.; (b) Defendants Teikoku Pharma USA, Inc. and Teikoku Seiyaku Co., Ltd.; and (c) Defendants Actavis plc. just before trial in the United States District Court for the Northern District of California. The Court preliminarily approved the settlements on May 1, 2018.

On September 20, 2018, Judge William H. Orrick issued a Final Judgment and Order, which provided $104.75 million in cash to settle the End-Payor Class’s claims. It dismissed the End-Pay Class’s claims with prejudice and without costs.